3.43 USD
▼-0.03-0.87%
盘后 3.45 -0.29%
2026-08-03
市值
$88.95M
市盈率
—
EPS
-1.87
股息率
—
52 周区间
3.01 – 12.99
成交量
57.43K
Beta
—
目标价
16.00
52W 低 3.0152W 高 12.99
价格走势
公司简介
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary bra...